Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Egg white extract could help tame blood sugar and pressure

NCT ID NCT06555393

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests whether a peptide called IRW, found in egg white hydrolysate, can help manage high blood sugar and blood pressure. About 28 participants at risk for or with type 2 diabetes will consume a smoothie with the peptide on four separate days, while a healthy control group does it once. Researchers will measure peptide levels in the blood, along with glucose, insulin, and blood pressure changes over a few hours.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bioactive peptide IRW from egg white hydrolysate
What this could lead to
If it works, this could point toward a natural dietary supplement to help control blood sugar and blood pressure.
What could go wrong
This is a very small, early-phase study (28 people) looking at short-term effects only. The peptide may not show meaningful benefits or may not be absorbed well.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 28 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Healthy control group: * Men and women aged between 18 and 70 years living in Edmonton (or Edmonton area/driving distance). * Normal weight (BMI below 25 kg/m2 or Asian population below 23 kg/m2 ) * Waist circumference below the following ethnic specific cut offs: Canada / USA: \<102 cm men and \<88 cm women; Europids, Middle-Eastern, Sub-Saharan African, and Mediterranean: \<94 cm men and \<80 cm women; Asians, Japanese, South and Central Americans: \<90 cm men and \<80 cm women * Fasting glucose \<5.6 mmol/L * HbA1c \<5.6 % * Blood pressure \<130/85 mmHg * Triglycerides \<1.7 mmol/L * HDL-Cholesterol \>1.03 mmol/L men and \>1.29 mmol/L women * Body weight stable (within 3% fluctuation) for at least 6 months prior to the study * Individuals who have never smoke, have smoke less than 100 cigarettes in their life or who are long term quitter (quit smoking a year or more ago) Individuals at risk of diabetes/having type 2 diabetes: * Men and women aged between 18 and 70 years living in Edmonton (or Edmonton area/driving distance). * Overweight or obesity (BMI above 25 kg/m2 or Asian population above 23 kg/m2) * Waist circumference at or above the following ethnic specific cut offs: Canada / USA: ≥ 102 cm men and ≥ 88 cm women; Europids, Middle-Eastern, Sub-Saharan African, and Mediterranean: ≥ 94 cm men and ≥ 80 cm women; Asians, Japanese, South and Central Americans: ≥ 90 cm men and ≥ 80 cm women * Fasting glucose ≥ 6.0 mmol/L * HbA1c ≥ 6.0 % * Body weight stable (within 3% fluctuation) for at least 6 months prior to the study * Individuals who have never smoke, have smoke less than 100 cigarettes in their life or who are long term quitter (quit smoking a year or more ago) Exclusion Criteria: * Individuals with a previous history of CVD, renal disorder, monogenic dyslipidemia, with endocrine disorders other than T2D * Individuals taking chronic anti-inflammatory drugs (including aspirin, antihistamines, and omega-3 supplements) * Pregnant/lactating women * Individuals aged above 70 years * Smokers (current smokers: daily/occasional and those who have smoked more than 100 cigarettes in their life) * Individuals with specific nutritional restrictions (e.g. vegetarianism excluding eggs from their diet, vegan or with egg allergy) will be excluded * Individuals with poorly controlled (HbA1c \>12.0%) diabetes or taking exogenous insulin will be excluded. Other anti-diabetic and lipid-lowering medications will be documented.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for High blood pressure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Alberta

    RECRUITING

    Edmonton, Alberta, T6G 2P5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.